본문 바로가기 대메뉴 바로가기

Department of Infectious Diseases Research
Securing technology for treating and controlling new and variant viruses and multi-drug resistant superbacteria

The Department has contributed to public safety by securing technologies for controlling high-risk infectious diseases to resolve daily problems and social issues related to the citizens’ healthy life.

Director
  • NameSoo Bong Han
  • Office+82-42-860-7133
  • E-mailsbhan@krict.re.kr
Soo Bong Han

Research goals

  • Development of innovative technology for treating and controlling high-risk viruses
  • Development of innovative technology for treating and controlling high-risk bacteria

Major research fields

  • Development of therapeutics for chronic hepatitis B virus
  • Development of therapeutics for picornavirus
  • Development of candidates for Gram negative bacteria therapeutics
  • Establishment of HTS system for Gram negative bacteria and discovery of effective materials
  • Development of clinical candidates for new anti-viral drugs that can effectively treat COVID-19

Key research accomplishments

  • [Patent] Antiviral compound, preparation method thereof, and pharmaceutical composition for use in preventing or treating viral diseases containing the same as an active ingredient - 2019
  • [Patent] Quinazoline derivatives, preparation method thereof, and pharmaceutical composition for treating influenza virus containing the same – 2019
  • [Patent] Compound for the treatment of diseases caused by coronavirus infection – 2018
  • [Patent] Novel benzothiophene derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating viral diseases containing the same as an active ingredient –2018
  • [Patent] Tetrahydrobenzothiophene derivatives, preparation method thereof, and pharmaceutical composition for prevention or treatment of the viral diseases containing the same
  • [Patent] Novel compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of disease caused by influenza virus infection containing the same as an active ingredient – 2017
  • Development of technology for simultaneously observe real-time behavior of label-free biomolecules, such as virus and bacteria, through various optical signals